As it deep­ens im­munol­o­gy bets, Sanofi inks small mol­e­cule pact with Bel­har­ra

Bel­har­ra Ther­a­peu­tics is rid­ing the waves of Sanofi’s bid to be­come an “im­munol­o­gy pow­er­house.

The Cal­i­for­nia biotech — whose name de­rives from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.